Literature DB >> 25691674

Will targeting Chk1 have a role in the future of cancer therapy?

Nandini Sakurikar1, Alan Eastman2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25691674     DOI： 10.1200/JCO.2014.60.0767

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  20 in total

1.  Finite Element Analysis of the Mouse Distal Femur with Tumor Burden in Response to Knee Loading.

Authors:  Feifei Jiang; Shengzhi Liu; Andy Chen; Bai-Yan Li; Alexander G Robling; Jie Chen; Hiroki Yokota
Journal:  Int J Orthop (Hong Kong)       Date:  2018-02-28

2.  Mechanistic Distinctions between CHK1 and WEE1 Inhibition Guide the Scheduling of Triple Therapy with Gemcitabine.

Authors:  Siang-Boon Koh; Yann Wallez; Charles R Dunlop; Sandra Bernaldo de Quirós Fernández; Tashinga E Bapiro; Frances M Richards; Duncan I Jodrell
Journal:  Cancer Res       Date:  2018-05-07       Impact factor: 12.701

Review 3.  Cell Cycle Regulation and Melanoma.

Authors:  Wen Xu; Grant McArthur
Journal:  Curr Oncol Rep       Date:  2016-06       Impact factor: 5.075

Review 4.  Treatment of Relapsed/Refractory Acute Myeloid Leukemia.

Authors:  Prithviraj Bose; Pankit Vachhani; Jorge E Cortes
Journal:  Curr Treat Options Oncol       Date:  2017-03

5.  LY2603618, a selective CHK1 inhibitor, enhances the anti-tumor effect of gemcitabine in xenograft tumor models.

Authors:  Darlene Barnard; H Bruce Diaz; Teresa Burke; Gregory Donoho; Richard Beckmann; Bonita Jones; David Barda; Constance King; Mark Marshall
Journal:  Invest New Drugs       Date:  2015-11-27       Impact factor: 3.850

6.  Synthesis and Antileukemic Activities of Piperlongumine and HDAC Inhibitor Hybrids against Acute Myeloid Leukemia Cells.

Authors:  Yi Liao; Xiaojia Niu; Bailing Chen; Holly Edwards; Liping Xu; Chengzhi Xie; Hai Lin; Lisa Polin; Jeffrey W Taub; Yubin Ge; Zhihui Qin
Journal:  J Med Chem       Date:  2016-08-24       Impact factor: 7.446

7.  Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress.

Authors:  Anish Thomas; Nobuyuki Takahashi; Vinodh N Rajapakse; Xiaohu Zhang; Yilun Sun; Michele Ceribelli; Kelli M Wilson; Yang Zhang; Erin Beck; Linda Sciuto; Samantha Nichols; Brian Elenbaas; Janusz Puc; Heike Dahmen; Astrid Zimmermann; Jillian Varonin; Christopher W Schultz; Sehyun Kim; Hirity Shimellis; Parth Desai; Carleen Klumpp-Thomas; Lu Chen; Jameson Travers; Crystal McKnight; Sam Michael; Zina Itkin; Sunmin Lee; Akira Yuno; Min-Jung Lee; Christophe E Redon; Jessica D Kindrick; Cody J Peer; Jun S Wei; Mirit I Aladjem; William Douglas Figg; Seth M Steinberg; Jane B Trepel; Frank T Zenke; Yves Pommier; Javed Khan; Craig J Thomas
Journal:  Cancer Cell       Date:  2021-04-12       Impact factor: 31.743

8.  Chemogenetic profiling identifies RAD17 as synthetically lethal with checkpoint kinase inhibition.

Authors:  John Paul Shen; Rohith Srivas; Andrew Gross; Jianfeng Li; Eric J Jaehnig; Su Ming Sun; Ana Bojorquez-Gomez; Katherine Licon; Vignesh Sivaganesh; Jia L Xu; Kristin Klepper; Huwate Yeerna; Daniel Pekin; Chu Ping Qiu; Haico van Attikum; Robert W Sobol; Trey Ideker
Journal:  Oncotarget       Date:  2015-11-03

9.  Targeting radioresistant breast cancer cells by single agent CHK1 inhibitor via enhancing replication stress.

Authors:  Yao Zhang; Jinzhi Lai; Zhanwen Du; Jinnan Gao; Shuming Yang; Shashank Gorityala; Xiahui Xiong; Ou Deng; Zhefu Ma; Chunhong Yan; Gonzalo Susana; Yan Xu; Junran Zhang
Journal:  Oncotarget       Date:  2016-06-07

10.  A subset of cancer cell lines is acutely sensitive to the Chk1 inhibitor MK-8776 as monotherapy due to CDK2 activation in S phase.

Authors:  Nandini Sakurikar; Ruth Thompson; Ryan Montano; Alan Eastman
Journal:  Oncotarget       Date:  2016-01-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.